Abstract: A topical composition includes a non-steroidal anti-inflammatory drug (NSAID) in an aqueous carrier system which contains a cationic galactomannan gum. The carrier system includes, in addition to water and the cationic galactomannan gum, a lactate ester of a C2 to C16 saturated aliphatic alcohol, a monoprotic arylalkanoic acid (pKa 3.8 to 5), a solubility enhancer, and a C2 to C8 saturated aliphatic alcohol.

Abstract: Provided herein are topical formulations. The topical formulation may comprise: (i) pregabalin, (ii) water, (iii) DMSO, (iv) a keto acid, and (v) and/or a fatty alcohol. The topical formulation may also comprise (i) pregabalin, (ii) DMSO, (iii) a keto acid and (iv) a fatty acid ester. It has been discovered that the combinations of DMSO with a keto acid such as levulinic acid and/or and a fatty acid ester such as lauryl lactate, or combinations of DMSO with a keto acid such as levulinic acid and/or with a fatty alcohol such as oleyl alcohol are excellent penetration enhancers and, as such, can be incorporated in a skin-applied formulation to facilitate administration of pregabalin.

Abstract: A topical composition includes a non-steroidal anti-inflammatory drug (NSAID) in an aqueous carrier system which contains a cationic galactomannan gum. The carrier system includes, in addition to water and the cationic galactomannan gum, a lactate ester of a C2 to C16 saturated aliphatic alcohol, a monoprotic arylalkanoic acid (pKa 3.8 to 5), a solubility enhancer, and a C2 to C8 saturated aliphatic alcohol.

Abstract: Provided herein are topical formulations. The topical formulation may comprise: (i) pregabalin, (ii) water, (iii) DMSO, (iv) a keto acid, and (v) and/or a fatty alcohol. The topical formulation may also comprise (i) pregabalin, (ii) DMSO, (iii) a keto acid and (iv) a fatty acid ester. It has been discovered that the combinations of DMSO with a keto acid such as levulinic acid and/or and a fatty acid ester such as lauryl lactate, or combinations of DMSO with a keto acid such as levulinic acid and/or with a fatty alcohol such as oleyl alcohol are excellent penetration enhancers and, as such, can be incorporated in a skin-applied formulation to facilitate administration of pregabalin.

Abstract: The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.

Abstract: Aqueous, topical compositions contain an allylamine or an azole as an antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), ethanol, water, and a cationic galactomannan gum.

Abstract: A topical composition includes a non-steroidal anti-inflammatory drug (NSAID) in an aqueous carrier system which contains a cationic galactomannan gum. The carrier system includes, in addition to water and the cationic galactomannan gum, a lactate ester of a C2 to C16 saturated aliphatic alcohol, a monoprotic arylalkanoic acid (pKa 3.8 to 5), a solubility enhancer, and a C2 to C8 saturated aliphatic alcohol.

Abstract: Aqueous, topical compositions contain an allylamine or an azole as an antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), ethanol, water, and a cationic galactomannan gum.

Abstract: Aqueous, topical antifungal compositions contain an allylamine or an azole as the antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), a C2 to C6 saturated aliphatic alcohol, and a cationic galactomannan gum.

Abstract: The present disclosure provides methods and compositions which treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms associated with peripheral neuropathies (e.g., neuropathic pain) or sunburn in a subject. Specifically, the present invention relates to topically administering a therapeutically effective amount of a pharmaceutically safe therapeutic agent directly to the region exhibiting pain in a subject.

Abstract: A sprayable analgesic composition is an aqueous ethanolic solution which contains a nonsteroidal anti-inflammatory drug (NSAID), lauryl lactate, lactic acid, glyceryl monolaurate, propylene glycol and optionally an alkoxylated alcohol.

Abstract: Aqueous, topical antifungal compositions contain an allylamine or an azole as the antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), a C2 to C6 saturated aliphatic alcohol, and a cationic galactomannan gum.

Abstract: The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.

Abstract: The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.

Abstract: The present invention relates to a topical composition and method of use, specifically an oil-in-water emulsion, comprised of sweet almond oil, lavender oil, rose oil, cinnamon bark oil, and coriander seed oil in a physiologically acceptable topical carrier. The composition is applied to a circumcised penis to enhance sensitivity, preferably twice daily for a time period of at least about two weeks. Thereafter a maintenance dose can be applied once a day to maintain a desired level of sensitivity.

Abstract: The present invention relates to a topical composition and method of use, specifically an oil-in-water emulsion, comprised of sweet almond oil, lavender oil, rose oil, cinnamon bark oil, and coriander seed oil in a physiologically acceptable topical carrier. The composition is applied to a circumcised human penis to enhance sensitivity, preferably twice daily for a time period of at least about two weeks. Thereafter a maintenance dose can be applied once a day to maintain a desired level of sensitivity.

Abstract: Provided herein are topical formulations. The topical formulation may comprise: (i) pregabalin, (ii) water, (iii) DMSO, (iv) a keto acid, and (v) and/or a fatty alcohol. The topical formulation may also comprise (i) pregabalin, (ii) DMSO, (iii) a keto acid and (iv) a fatty acid ester. It has been discovered that the combinations of DMSO with a keto acid such as levulinic acid and/or and a fatty acid ester such as lauryl lactate, or combinations of DMSO with a keto acid such as levulinic acid and/or with a fatty alcohol such as oleyl alcohol are excellent penetration enhancers and, as such, can be incorporated in a skin-applied formulation to facilitate administration of pregabalin.

Abstract: The present invention relates to a topical composition and method of use, specifically an oil-in-water emulsion, comprised of sweet almond oil, lavender oil, rose oil, cinnamon bark oil, and coriander seed oil in a physiologically acceptable topical carrier. The composition is applied to a circumcised human penis to enhance sensitivity, preferably twice daily for a time period of at least about two weeks. Thereafter a maintenance dose can be applied once a day to maintain a desired level of sensitivity.

Abstract: The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.

Abstract: A transdermal patch suitable for releasing a stimulant such as caffeine for an extended time period utilizes a pressure sensitive acrylic adhesive matrix constituted by an acrylic adhesive having hydroxy groups and an acrylic adhesive without hydroxy, groups, preferably in a respective weight ratio of about 2 to about 3. A suitable caffeine source is caffeine-fortified guarana seed extract, caffeine, a caffeine salt, and the like.